Pfizer gets FDA approval for rheumatoid arthritis treatment

Share this article:
Federal regulators approved Pfizer's new Xeljanz treatment for rheumatoid arthritis Tuesday. The potentially lucrative drug is now poised to enter a market that already features Humira, Abbott Laboratories' top-selling rheumatoid arthritis treatment.

The Food and Drug Administration approved Xeljanz for patients with moderate to severe rheumatoid arthritis who did not benefit from the oral treatment methotrexate. Xeljanz can be used with methotrexate and certain other treatments. Industry analysts have predicted the new drug, also known as tofacitinib, could grow to sales of $3 billion annually.

Xeljanz is taken in 5-milligram pills twice daily. Abbott's $8 billion-a-year Humira requires an injection every two weeks. The FDA said it requires more safety data on a 10-milligram, twice-daily dose of Xeljanz that  Pfizer also submitted.

About 1.3 million people in the United States suffer from rheumatoid arthritis, which can cause problems in wounds healing.

Share this article:

More in News

Expert says providers often wrongly threatened by PEPPER reports

Instead of fearing further scrutiny by federal authorities, providers should embrace the opportunity to get feedback in the form of PEPPER reports, legal experts said Monday at the LeadingAge annual meeting in Nashville.

Healthcare reform already driving diverse, dynamic long-term care models, LeadingAge leaders say

Healthcare reform already driving diverse, dynamic long-term care ...

One way to gauge the effects is healthcare reform is by looking at ongoing changes to the continuing care retirement community model, LeadingAge officials said Monday at the association's annual ...

Federal court: Nursing home can be sued for firing hairdresser who can ...

Is the ability to transport residents in their wheelchairs an essential function of a nursing home hairdresser? A federal appeals court says it's a valid question and is allowing a hairdresser to sue a facility that fired her.